You are here : Network » Registry for VIC » Member Details Little font Medium font Large font

Associate Professor Susan Charman

Position

Associate Professor in Pharmaceutics
Director, Centre for Drug Candidate Optimisation

Address

Centre for Drug Candidate Optimisation
Monash Institute for Pharmaceutical Sciences
381 Royal Parade

Parkville, Vic 3052

 

Research interests

My research is centred on the development and application of lead optimisation technologies to identify, design and select high quality drug candidates with particular emphasis on drug candidates for neglected diseases. My research focuses on the relationship between physicochemical properties of drug candidates and their absorption, distribution and elimination characteristics.

Qualifications

PhD in Pharmaceutics

Ten Most Significant Publications

  1. .L. Vennerstrom, S. Arbe-Barnes, R. Brun, S.A. Charman, F.C.K. Chiu, J. Chollet, Y. Dong, A. Dorn, D. Hunziker, H. Matile, K.A. McIntosh, M. Padmanilayam, J. Santo Tomas, C. Scheurer, B. Scorneaux, Y. Tang, H. Urwyler, S. Wittlin and W.N. Charman. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature, 430, 900-904, 2004.
  2. Y. Dong, J. Chollet, H. Matile, S.A. Charman, F.C.K. Chiu, W.N. Charman, B. Scorneaux, H. Urwyler, J. Santo Tomas, C. Scheurer, A. Dorn, X. Wang, J.M. Karle, Y. Tang, S. Wittlin, R. Brun, and J.L. Vennerstrom. Spiro and dispiro-1,2,4-trioxolanes as antimalarial peroxides: charting a workable SAR using simple prototypes. J. Med. Chem., 48, 4953-4961, 2005.
  3. D.J. Creek, W.N. Charman, F.C.K. Chiu, R.J. Prankerd, K.J. McCullough, Y. Dong, J.L. Vennerstrom and S.A. Charman, Iron-mediated degradation kinetics of substituted dispiro-1,2,4-trioxolane antimalarials. J. Pharm. Sci., 96, 2945-2956, 2007.
  4. D.J. Creek, W.N. Charman, F.C.K. Chiu, R.J. Prankerd, Y.Dong, J.L. Vennerstrom and S.A. Charman. Relationship between antimalarial activity and haem alkylation for spiro- and dispiro-1,2,4-trioxolane antimalarials. Antimicrob. Agents Chemother., in press.
  5. S.A. Charman, W.N. Charman, T.D. Wilson, M.C. Rogge, F.J. Dutko and C.W. Pouton. Self-emulsifying drug delivery systems: Formulation and biopharmaceutic evaluation of an investigational lipophilic compound. Pharm. Res., 9, 87-93, 1992.
  6. C.J.H. Porter, S.A. Charman, and W.N. Charman. Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: Effect of lipid vehicle dispersion. J. Pharm. Sci., 85, 351-356, 1996.
  7. S.A. Charman, K.L. Mason and W.N. Charman. Techniques for assessing the effects of pharmaceutical excipients on the aggregation of porcine growth hormone. Pharm. Res., 7, 954-962, 1993.
  8. C.S. Perry, F.C.K. Chiu, K.A. McIntosh, R.J. Prankerd, W.N. Charman and S.A. Charman. Alteration of the intravenous pharmacokinetics of a synthetic ozonide antimalarial in the presence of a modified cyclodextrin. J. Pharm. Sci., 95, 256-267, 2006.
  9. C.J.H Porter and S.A. Charman. Lymphatic transport of proteins after subcutaneous administration. J. Pharm. Sci., 89, 297-310, 2000.
  10. G.A. FitzGerald, M. Lupinetti, S.A. Charman and W.N. Charman. Presystemic acetylation of platelets by aspirin: Reduction in the rate of drug delivery to improve biochemical selectivity for thromboxane A2. J. Pharmacol. Exp. Ther., 259, 1043-1049, 1991.

 

Currently Held Grants

Development of therapeutic agents that target carbonic anhydrase enzymes.

Optimizing novel dihydroorotate dehydrogenase inhibitors for treating malaria. National Institute of Allergy and Infectious Diseases, NIH. Collaboration between University of Texas Southwestern Medical Center, University of Washington, and Monash University (role co-Inv).

Collaborative lead optimisation studies with various commercial partners, conducted through the Centre for Drug Candidate Optimisation (role as either PI or co-PI).

Synthetic peroxide drug discovery program. Medicines for Malaria Venture, Geneva, Switzerland. Collaboration between University of Nebraska, Swiss Tropical Institute, F. Hoffman La-Roche, and Monash University (role co-Inv).

New inhibitors of Plasmodium dihydrofolate reductase. Medicines for Malaria Venture, Geneva, Switzerland. Collaboration between BIOTEC, London School of Hygiene and Tropical Medicine, and Monash University (role co-Inv).

Novel, Orally Available Drug Candidates For Trypanosome Infections, Drugs for Neglected Diseases Initiative (DNDi), Geneva, Switzerland. Collaboration between Murdoch University and Monash University (role co-Inv).